HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Myositis Ossificans

A disease characterized by bony deposits or the ossification of muscle tissue.
Also Known As:
Fibrodysplasia Ossificans Progressiva
Networked: 233 relevant articles (6 outcomes, 14 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Heterotopic Ossification (Ectopic Ossification)
2. Myoclonus (Nocturnal Myoclonus)
3. Osteogenesis Imperfecta (Lobstein Disease)
4. Sarcoma (Soft Tissue Sarcoma)
5. Osteitis Deformans (Paget's Disease of Bone)

Experts

1. Kaplan, Frederick S: 29 articles (05/2014 - 01/2003)
2. Shore, Eileen M: 29 articles (05/2014 - 01/2003)
3. Glaser, David L: 10 articles (09/2009 - 09/2003)
4. Katagiri, Takenobu: 6 articles (01/2015 - 12/2008)
5. Pignolo, Robert J: 6 articles (12/2012 - 02/2007)
6. Xu, Meiqi: 6 articles (01/2010 - 05/2006)
7. Yu, Paul B: 5 articles (09/2015 - 03/2009)
8. Bullock, Alex N: 5 articles (10/2014 - 03/2011)
9. Triffitt, James T: 4 articles (01/2013 - 05/2006)
10. de Gorter, David J J: 4 articles (01/2013 - 01/2010)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Myositis Ossificans:
1. Serine (L-Serine)FDA Link
03/01/2011 - "A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date."
03/01/2011 - "Fibrodysplasia Ossificans Progressiva (FOP) is a rare, autosomal dominant condition, classically characterised by heterotopic ossification beginning in childhood and congenital great toe malformations; occurring in response to a c.617 G > A ACVR1 mutation in the functionally important glycine/serine-rich domain of exon 6. Here we describe a novel c.587 T > C mutation in the glycine/serine-rich domain of ACVR1, associated with delayed onset of heterotopic ossification and an exceptionally mild clinical course. "
06/01/2012 - "Fibrodysplasia ossificans progressiva (FOP) causes extensive heterotopic bone formation due to heterozygous mutations in the glycine-serine activation domain of ACVR1 (ALK2), a bone morphogenetic protein type I receptor. "
11/01/2009 - "Patients with classic fibrodysplasia ossificans progressiva, a disorder characterized by extensive extraskeletal endochondral bone formation, share a recurrent mutation (R206H) within the glycine/serine-rich domain of ACVR1/ALK2, a bone morphogenetic protein type I receptor. "
09/01/2007 - "Individuals with fibrodysplasia ossificans progressiva are born with malformations of the great toes and develop a heterotopic skeleton during childhood because of an identical heterozygous mutation in the glycine-serine activation domain of ACVR1, a bone morphogenetic protein type I receptor. "
2. Glycine (Aminoacetic Acid)FDA LinkGeneric
03/01/2011 - "A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date."
03/01/2011 - "Fibrodysplasia Ossificans Progressiva (FOP) is a rare, autosomal dominant condition, classically characterised by heterotopic ossification beginning in childhood and congenital great toe malformations; occurring in response to a c.617 G > A ACVR1 mutation in the functionally important glycine/serine-rich domain of exon 6. Here we describe a novel c.587 T > C mutation in the glycine/serine-rich domain of ACVR1, associated with delayed onset of heterotopic ossification and an exceptionally mild clinical course. "
06/01/2012 - "Fibrodysplasia ossificans progressiva (FOP) causes extensive heterotopic bone formation due to heterozygous mutations in the glycine-serine activation domain of ACVR1 (ALK2), a bone morphogenetic protein type I receptor. "
11/01/2009 - "Patients with classic fibrodysplasia ossificans progressiva, a disorder characterized by extensive extraskeletal endochondral bone formation, share a recurrent mutation (R206H) within the glycine/serine-rich domain of ACVR1/ALK2, a bone morphogenetic protein type I receptor. "
09/01/2007 - "Individuals with fibrodysplasia ossificans progressiva are born with malformations of the great toes and develop a heterotopic skeleton during childhood because of an identical heterozygous mutation in the glycine-serine activation domain of ACVR1, a bone morphogenetic protein type I receptor. "
3. Isotretinoin (Accutane)FDA LinkGeneric
4. SteroidsIBA
5. Alendronate (Alendronate Sodium)FDA LinkGeneric
6. Calcitonin (Calcitonin, Eel)FDA LinkGeneric
7. Alkaline PhosphataseIBA
8. Etidronic Acid (HEDP)FDA LinkGeneric
9. Bone Morphogenetic Protein 4IBA
10. CalciumIBA

Therapies and Procedures

1. General Anesthesia
2. Bone Marrow Transplantation (Transplantation, Bone Marrow)
3. Microspheres (Microsphere)
4. Arthroplasty
5. Anesthesia